Drug intelligence / Profile preview

pemetrexed + temsirolimus

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Intravenous

Overview

Pemetrexed + temsirolimus is a combination therapy that has been investigated for the treatment of non-small cell lung cancer (NSCLC). Pemetrexed is an anti-folate chemotherapeutic agent approved for use in NSCLC, while temsirolimus is an inhibitor of the mammalian target of rapamycin (mTOR) pathway, which is implicated in lung cancer development. The combination has been evaluated in a phase I clinical trial to determine its safety, tolerability, and maximum tolerated dose in patients with advanced non-squamous NSCLC.

Targets

DHFR (Dihydrofolate reductase)GART (GAR transformylase)TS (Thymidylate synthase)mTOR (Mammalian target of rapamycin kinase)

Beyond the preview

Go deeper on pemetrexed + temsirolimus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pemetrexed + temsirolimus.

Explore the full profile